-+ 0.00%
-+ 0.00%
-+ 0.00%

Hengrui Pharma Signs Exclusive License With Novo For Once-Weekly Oral GLP-1/GIP Agonist HRS-1596, Featuring $300M Upfront In Up To $2.6B Deal

Benzinga·09/29/2026 07:13:45
Listen to the news
  • HRS-1596 is a phase I-ready GLP-1/GIP dual receptor agonist for once-weekly oral dosing          
  • Total potential deal value is up to 2.6 billion US dollars, including 300 million dollars upfront, as well as potential sales royalties